Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 17/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035744 | 0.89 | CCR9 (0.47) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1037648 | 0.79 | HSD17B2 (0.50) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1033740 | 0.79 | ALDH1A1 (0.47) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1036879 | 0.77 | HSD17B2 (0.49) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1038886 | 0.76 | HSD17B2 (0.47) | CCR9HSD17B2PIK3CD | |
| SCHEMBL10223690 | 0.76 | CCR9 (0.52) | CCR9HSD17B2PIK3CD | |
| SCHEMBL10305654 | 0.76 | HSD17B2 (0.61) | CCR9HSD17B2PIK3CD | |
| SCHEMBL2978871 | 0.76 | CCR9 (0.48) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1035802 | 0.75 | CCR9 (0.44) | CCR9HSD17B2PIK3CD | |
| SCHEMBL1033742 | 0.74 | CCR9 (0.50) | CCR9HSD17B2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049515-A2 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS | ChemoCentryx Inc (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008375-A2 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |